Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Emerging Infectious Diseases|July 18, 2018
Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra LeonePatrick J Howlett, Anna R Walder, Durodami R Lisk, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|November 13, 2025
Daily stress and worry are additional triggers of symptom fluctuations in individuals living with Long COVID: results from an intensive longitudinal cohort studyDaryl B O'Connor, Darren C Greenwood, Maedeh Mansoubi, et al.
The Lancet. Infectious Diseases|March 4, 2017
Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virusJudith R Glynn, Hilary Bower, Sembia Johnson, et al.
The Lancet Regional Health. Europe|October 9, 2024
Physical, cognitive, and social triggers of symptom fluctuations in people living with long COVID: an intensive longitudinal cohort studyDarren C Greenwood, Maedeh Mansoubi, Nawar D Bakerly, et al.
Human Vaccines & Immunotherapeutics|November 13, 2012
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trialRosalind Rowland, Ansar A Pathan, Iman Satti, et al.
Nature|January 28, 2021
Ebola virus antibody decay-stimulation in a high proportion of survivorsCharlene Adaken, Janet T Scott, Raman Sharma, et al.
Frontiers in Immunology|May 20, 2022
Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial VirusAlexander Stewart, Emma Sinclair, Joseph Chi-Fung Ng, et al.
Transfusion|March 25, 2018
Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra LeoneRichard S Tedder, Dhan Samuel, Steve Dicks, et al.
Antimicrobial Agents and Chemotherapy|June 24, 2025
Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trialMatthew Tate, Christopher J R Illingworth, Gordon MacGregor, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 5, 2021
Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19Daniel Munblit, Polina Bobkova, Ekaterina Spiridonova, et al.
Pageof 5